A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy.

ABSTRACT:

Abstract

There is increasing evidence that novel coronavirus disease 2019 (COVID-19) leads to a significant coagulopathy, a phenomenon termed "COVID-19 associated coagulopathy." COVID-19 has been associated with increased rates of both venous and arterial thromboembolic events, a source of significant morbidity and mortality in this disease. Further evidence suggests a link between the inflammatory response and coagulopathy associated with COVID-19. This presents a unique set of challenges for diagnosis, prevention, and treatment of thrombotic complications. In this review, we summarize and discuss the current literature on laboratory coagulation disruptions associated with COVID-19 and the clinical effects of thromboembolic events including pulmonary embolism, deep vein thrombosis

SUBMITTER: Goswami J 

PROVIDER: S-EPMC8122038 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature